
    
      About 60 patients with HCC, who had received complete resection or TACE and got Complete
      remission (CR) or partial response (PR), will be randomly divided into group A (receive
      DC-CIK treatment) or group B (just regularly follow up), and the randomize ratio will be 1:1.
      Patients in group A will receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks).
      Patients in group B will have no anti-tumor therapy.
    
  